Global $10+ Billion Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight, 2026

    NEXT STORY
    Zai Lab Announces First Patients Treated in Separate Phase 1b and Registrational Bridging Studies
    PREV STORY
    ContraFect Announces One-for-Ten Reverse Stock Split
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    FDA Approves Radius Health’s TYMLOS™ (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture

    TYMLOS is the first new anabolic (bone building) agent for postmenopausal women with osteoporosis ...

    author_avatar
    NASDAQ Market News

    Reata Pharmaceuticals, Inc. Appoints Geoffrey A. Block, M.D. as Vice President, Nephrology

    author_avatar
    NASDAQ Market News

    RedHill Biopharma Announces FDA Approval of Talicia® for Treatment of H. pylori in Adults

    author_avatar
    NASDAQ Market News